RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Status Recruiting

Clinical Trial Summary

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
T Acute Lymphoblastic Leukemia
T-lymphoblastic Lymphoma

Clinical Trial Details

NCT number	NCT04620655
Study type	Interventional
Source	Hebei Yanda Ludaopei Hospital
Contact	Xian Zhang
Phone	+86-13641041596
Email	zhxian2@126.com
Status	Recruiting
Phase	N/A
Start date	November 15, 2020
Completion date	November 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02484430` - Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	Phase 2
Terminated	`NCT03519984` - EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia	Phase 1
Recruiting	`NCT04128501` - Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	Phase 2
Recruiting	`NCT04582487` - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL	N/A
Recruiting	`NCT00501826` - Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Phase 2
Withdrawn	`NCT02538926` - Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Phase 2
Active, not recruiting	`NCT00408005` - Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Phase 3
Terminated	`NCT02767934` - Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia	Phase 2
Withdrawn	`NCT06210750` - Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	Phase 2
Recruiting	`NCT03007147` - Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Phase 3
Recruiting	`NCT05602194` - Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma	Phase 3
Recruiting	`NCT03504644` - Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia	Phase 1/Phase 2